Table 3 Case base results
Atezolizumab | Pembrolizumab | Incremental | ||||
|---|---|---|---|---|---|---|
Cut-off 2018 | Cut-off 2020 | Cut-off 2018 | Cut-off 2020 | Cut-off 2018 | Cut-off 2020 | |
Costs in ‘PFS’state | € 105,418 | € 149,213 | € 160,618 | € 227,894 | € − 55,200 | € − 78,681 |
Treatment (intevention) | € 95,225 | € 136,135 | € 151,300 | € 216,299 | €− 56,075 | € − 80,164 |
Other healthcare costs | € 10,193 | € 13,079 | € 9,318 | € 11,595 | € + 875 | € + 1,494 |
Costs in ‘PPS’state | € 14,307 | € 12,171 | € 12,778 | € 15,588 | € + 1,529 | € − 3,417 |
Subsequent treatment | € 5,681 | € 5,534 | € 5,681 | € 5,534 | 0 | 0 |
Other healthcare costs | € 8,626 | € 6,637 | € 7,097 | € 10,054 | € + 1,529 | €-3,417 |
Costs ‘end-of-life’ | € 11,176 | € 11,477 | € 11,766 | € 11,286 | € − 590 | € + 191 |
Total costs | € 130,901 | € 172,861 | € 185,162 | € 254,769 | € − 54,261 | €− 81,907 |
LYs in PFS | 1.93 | 2.15 | 1.74 | 1.79 | + 0.18 | + 0.36 |
LYs in progression | 2.92 | 2.25 | 2.41 | 3.41 | + 0.52 | − 1.16 |
Total LYs | 4.85 | 4.40 | 4.15 | 5.20 | + 0.70 | − 0.80 |
QALYs in PFS | 0.99 | 1.43 | 1.06 | 1.61 | − 0.07 | − 0.18 |
QALYs in progression | 2.46 | 1.73 | 1.97 | 2.27 | + 0.49 | − 0.54 |
Total QALYs | 3.45 | 3.16 | 3.04 | 3.88 | + 0.42 | − 0.72 |
ICER (€/LY gained) | Dominant* | Less LY*, less cost | ||||
ICUR (€/QALY gained) | Dominant* | Less QALY*, less cost | ||||